ダウンロード数: 140
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
jnnp-2015-312036.pdf | 444.27 kB | Adobe PDF | 見る/開く |
タイトル: | Induced pluripotent stem cells in Parkinson's disease: scientific and clinical challenges |
著者: | Xiao, Bin Ng, Huck Hui Takahashi, Ryosuke https://orcid.org/0000-0002-1407-9640 (unconfirmed) Tan, Eng King |
著者名の別形: | 髙橋, 良輔 |
発行日: | Jul-2016 |
出版者: | BMJ Publishing Group |
誌名: | Journal of Neurology, Neurosurgery and Psychiatry |
巻: | 87 |
号: | 7 |
開始ページ: | 697 |
終了ページ: | 702 |
抄録: | Induced pluripotent stem cells (iPSCs), which greatly circumvent the ethical issue of human embryonic stem cells (ESCs), can be induced to differentiate to dopaminergic (DA) neurons, and hence be used as a human disease model for Parkinson's disease (PD). iPSCs can be also utilised to probe the mechanism, and serve as an 'in vivo' platform for drug screening and for cell-replacement therapies. However, any clinical trial approaches should be extensively supported by validated robust biological evidence (based on previous experience with fetal mesencephalic transplantation), in particular, the production and selection of the 'ideal' neurons (functional units with no oncological risk), together with the careful screening of appropriate candidates (such as genetic carriers), with inbuilt safeguards (safety studies) in the evaluation and monitoring (functional neuroimaging of both DA and non-DA system) of trial subjects. While iPSCs hold great promise for PD, there are still numerous scientific and clinical challenges that need to be surmounted before any clinical application can be safely introduced. |
著作権等: | © 2016 by the BMJ Publishing Group Ltd. |
URI: | http://hdl.handle.net/2433/218753 |
DOI(出版社版): | 10.1136/jnnp-2015-312036 |
PubMed ID: | 26833176 |
出現コレクション: | 学術雑誌掲載論文等 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。